OTCPK:BLGO

Stock Analysis Report

Executive Summary

BioLargo, Inc. operates as a technology developer and environmental engineering company in the United States.


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has BioLargo's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLGO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.4%

BLGO

-8.5%

US Chemicals

-7.6%

US Market


1 Year Return

5.3%

BLGO

-13.0%

US Chemicals

10.2%

US Market

Return vs Industry: BLGO exceeded the US Chemicals industry which returned -13.4% over the past year.

Return vs Market: BLGO underperformed the US Market which returned 10.5% over the past year.


Shareholder returns

BLGOIndustryMarket
7 Day-5.4%-8.5%-7.6%
30 Day-4.5%-5.8%-4.5%
90 Day-16.0%-7.9%-0.6%
1 Year5.3%5.3%-0.6%-13.0%12.5%10.2%
3 Year-58.0%-58.0%17.1%-5.6%37.1%28.3%
5 Year-46.2%-46.2%27.3%-0.2%60.8%43.2%

Price Volatility Vs. Market

How volatile is BioLargo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioLargo undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether BioLargo is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioLargo has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BLGO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BioLargo regulatory filings here.
  • Explore potentially undervalued companies in the Materials industry.

Future Growth

How is BioLargo forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.2%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioLargo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BioLargo performed over the past 5 years?

-21.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLGO is currently unprofitable.

Growing Profit Margin: BLGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLGO is unprofitable, and losses have increased over the past 5 years at a rate of -21.2% per year.

Accelerating Growth: Unable to compare BLGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLGO is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-15.9%).


Return on Equity

High ROE: BLGO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BioLargo's financial position?


Financial Position Analysis

Short Term Liabilities: BLGO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BLGO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BLGO has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BLGO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: BLGO has a low level of unsold assets or inventory.

Debt Coverage by Assets: BLGO has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLGO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BLGO has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21.1% each year


Next Steps

Dividend

What is BioLargo's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%4.0%industryaverage2.4%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BLGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLGO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.0yrs

Average management tenure


CEO

Dennis Calvert (56yo)

17.7yrs

Tenure

US$655,748

Compensation

Mr. Dennis P. Calvert serves as the Chairman of the Board at BioLargo, Inc. and has been its Chief Executive Officer and President since June 28, 2002. Mr. Calvert has an extensive entrepreneurial backgrou ...


CEO Compensation Analysis

Compensation vs Market: Dennis's total compensation ($USD655.75K) is about average for companies of similar size in the US market ($USD524.26K).

Compensation vs Earnings: Dennis's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dennis Calvert
Chairman17.7yrsUS$655.75k4.39% $1.6m
Charles Dargan
Chief Financial Officer12yrsUS$87.75k0.25% $86.8k
Joseph Provenzano
VP of Operations17.7yrsUS$223.94k0.78% $274.4k
Kenneth Code
Chief Science Officer & Director12.8yrsUS$301.20k0.75% $263.7k
Mitch Noto
Director of Corporate Development0.5yrsno datano data

12.0yrs

Average Tenure

60yo

Average Age

Experienced Management: BLGO's management team is seasoned and experienced (12 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dennis Calvert
Chairman17.7yrsUS$655.75k4.39% $1.6m
Joseph Provenzano
VP of Operations17.7yrsUS$223.94k0.78% $274.4k
Kenneth Code
Chief Science Officer & Director12.8yrsUS$301.20k0.75% $263.7k
John Runyan
Independent Director8.3yrsUS$75.00k0.16% $56.0k
Kent Roberts
Independent Director8.5yrsUS$60.00k0.36% $127.4k
Dennis Marshall
Independent Director13.8yrsUS$75.00k0.20% $71.4k
Jack Strommen
Independent Director2.7yrsUS$60.00k2.73% $965.3k

10.7yrs

Average Tenure

59yo

Average Age

Experienced Board: BLGO's board of directors are seasoned and experienced ( 10.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.6%.


Top Shareholders

Company Information

BioLargo, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioLargo, Inc.
  • Ticker: BLGO
  • Exchange: OTCPK
  • Founded:
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: US$35.380m
  • Shares outstanding: 168.47m
  • Website: https://www.biolargo.com

Number of Employees


Location

  • BioLargo, Inc.
  • 14921 Chestnut Street
  • Westminster
  • California
  • 92683
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLGOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2007

Biography

BioLargo, Inc. operates as a technology developer and environmental engineering company in the United States. The company operates through Odor-No-More, BLEST, BioLargo Water, and Clyra Medical segments. Its platform technology, Advanced Oxidation System (AOS) is a water treatment system for decontamination and disinfection. The company offers odor and volatile organic compound control products, and AOS water treatment technologies, as well as professional engineering and consulting services. In addition, it offers wound care products for traumatic injury, diabetic ulcers, and chronic hard-to-heal wounds. The company provides its products under the CupriDyne Clean, Nature’s Best Science, and Deodorall brand names. BioLargo, Inc. is based in Westminster, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/27 00:46
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.